(LifeSiteNews) — Pfizer on Thursday officially requested an emergency use authorization (EUA) to dole out its experimental COVID vaccine to young children between the ages of 5 and 11.
In an October 7 tweet announcing the move, Pfizer argued that its request seeking an EUA from the Food and Drug Administration (FDA) is “an important step in our ongoing effort against #COVID19.”
“We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat,” the pharmaceutical company added.
The news comes in spite of the fact that children are at extremely low risk of suffering severe complications or death from contracting COVID-19, and regardless of studies showing the jabs themselves present significant health risks to young people.
UPDATE: We and @BioNTech_Group officially submitted our request to @US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12. pic.twitter.com/72Z2HXlkOx
— Pfizer Inc. (@pfizer) October 7, 2021
School districts and governments have begun to mandate the jabs for “eligible” students attending classes during the 2021-2022 school year.
On Friday, California’s Democratic Gov. Gavin Newsom announced he would make the injections mandatory for all “eligible” students participating in in-person learning at both public and private schools.
The shots currently have an EUA for young people aged 12 to 15, while children under the age of 12 are considered “ineligible” to get the jab. The FDA already granted full approval for the Pfizer-BioNTech double-dose drug for anyone aged 16 or over in August.
If the FDA clears Pfizer’s request, all children attending public or private schools in California, from kindergarten through high school, will be required to get the shot.
The move to inoculate children against the coronavirus fails to acknowledge evidence that children are at extremely low risk of spreading or suffering serious effects from the coronavirus.
In July, a team of researchers with Johns Hopkins School of Medicine “analyze[d] approximately 48,000 children under 18 diagnosed with Covid in health-insurance data from April to August 2020,” finding a “mortality rate of zero among children without a pre-existing medical condition such as leukemia.”
As previously reported by LifeSite, the discovery led the team’s head researcher, Dr. Marty Makary, to accuse the CDC of basing its advocacy of school COVID vaccination on “flimsy data.”
Meanwhile, studies indicate children are more likely to suffer adverse reactions to the experimental injections than they are to become seriously ill from COVID-19.
A September 20 safety report published by the Federal Institute for Vaccines and Biomedicines in Germany found that the number of reported cases of suspected adverse effects following COVID-19 vaccination in children aged 12 to 17 has exceeded the total number of COVID-related hospitalizations for children within the same age group since the beginning of the pandemic.
Studies published after the jabs were authorized for teenagers have shown that young people, especially teenage boys, are at serious risk of developing severe side effects to the experimental COVID-19 drugs, including heart inflammation.
In June, Pfizer/BioNTech and Moderna were forced to add a risk of heart inflammation to the fact sheets for their COVID-19 drugs after 1,200 cases of heart inflammation after vaccination, mostly in males under age 30, were reported to the government.
Last month, a University of California-led study found that for teenage boys the risk of heart inflammation after getting a COVID shot was four to six times as high as the risk of being hospitalized with COVID-19.
In addition to posing a significant risk to children who are otherwise not in serious danger from COVID-19, the jabs have not been proven to stop the spread of the virus.
Acknowledging that as of yet its drugs have not been “approved or authorized” by the FDA for use in young children, Pfizer said the shots have been “authorized to prevent COVID-19 in ages 12+.”
However the Centers for Disease Control and Prevention has admitted that the injections are “not 100% effective” at preventing the transmission of the virus, and that “[v]accine breakthrough infections are expected.”
After recording over 9,000 breakthrough cases by late April, in May the CDC stopped reporting breakthrough cases unless they ended in hospitalization or death.
In August, the CDC director acknowledged the shots did not stop transmission of the virus.
“Our vaccines are working exceptionally well. They continue to work well with Delta with regard to severe illness and death,” CDC director Rochelle Walensky said. “But what they can’t do anymore is prevent transmission.”
If given the green-light by the FDA, Pfizer’s mRNA injections could be rolled out for children within weeks.
According to CNN, the FDA’s Vaccines and Related Biological Products Advisory Committee is set to convene later this month and will discuss Pfizer’s request.
“If the committee recommends the shot and FDA OKs it, a panel of CDC vaccine advisers will meet to consider whether to recommend its use in this age group,” the report stated. “Once the CDC signs off, administration could begin as soon as supplies of the child-sized doses are in pediatricians offices and other sites.”
Pending approval by the FDA and CDC, children would become “eligible” for the shots by the end of October or early November.